Mursla Bio is boosted by success of EvoLiver’s biopsy-based blood test
The results of Mursla Bio’s EvoLiver dynamic biopsy-based blood test show “far greater sensitivity than standard techniques” according to data presented at AASLD Liver Meeting 2024.
Dr Tomás Dias, Mursla Bio’s CSO, presented data from the study at one of the largest medical conferences, AASLD’s (American Association for the Study of Liver Diseases) The Liver Meeting, which took place in San Diego on 17 November.
The presentation, titled ‘Novel multiomics biomarker signature derived from blood circulating hepatocyte-extracellular vesicles for the early detection of HCC’, showed 86 per cent early-stage sensitivity at 88 per cent specificity for liver cancer surveillance among cirrhotic, high-risk patients with diverse etiologies.
The results are based on 464 patient samples, primarily collected prospectively, within a Western population, representing etiologies such as MASH/fatty liver disease, alcoholic liver disease and hepatitis.
This “validates clinical value of multi-omics content in organ-specific extracellular vesicles for liver cancer detection”, according to a Mursla Bio spokesperson.
Mursla Bio is headquartered on Cambridge Science Park and also has a facility in Boston, Massachusetts. Founded in 2017, the biotech’s mission is to significantly improve cancer outcomes for at-risk patients through the power of dynamic biopsy.
Dynamic biopsy is made possible by advanced extracellular vesicle (EV) science and an innovative approach called extracellular omics, supported by Mursla Bio’s pioneering technologies. These technologies include organ-specific EV isolation from biofluids for precise targeting, an AI-enabled multi-omics workflow for disease biomarker identification, and a scalable assay platform using optimal biomarkers for clinical use.
Pierre Arsène, founder and CEO of Mursla Bio, said: “Our flagship test has shown that our pioneering method of non-invasively capturing dynamic cellular processes from specific tissues via organ-specific EVs can detect early-stage HCC with far greater sensitivity than standard techniques.
“Earlier detection is critical to improving survival rates, as it enables access to effective treatments such as ablation, resection, or transplant. Our blood modality is also a more convenient method that will increase patient adherence to surveillance testing. EvoLiver represents an important step forward in the way liver cancer is detected and monitored.”
To date the company has raised $547,000 in a seed round led by Future Fund in September, 2020.
